Evidence map›Paper›PMID 27121323›Full record

ArticleOncotarget2016

Gene expression in normal-appearing tissue adjacent to prostate cancers are predictive of clinical outcome: evidence for a biologically meaningful field effect.

Cristina Magi-Galluzzi, Tara Maddala, Sara Moscovita Falzarano, Diana B Cherbavaz, Nan Zhang, Dejan Knezevic, Phillip G Febbo, Mark Lee, Hugh Jeffrey Lawrence, Eric A Klein

Open access · diamondAbstract readComparative Study
In one paragraph

Article in Oncotarget, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
2.8field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 23 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Observational
  12. Loss ofCancer research · 2017
    Article
  13. Article
  14. Tissue-based biomarkers in prostate cancer.Expert review of precision medicine and drug development · 2017
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Cristina Magi-GalluzziPathology and Laboratory Medicine Institute, Cleveland Clinic, Cleveland, Ohio, USA.
Tara MaddalaGenomic Health, Inc., Redwood City, California, USA.
Sara Moscovita FalzaranoPathology and Laboratory Medicine Institute, Cleveland Clinic, Cleveland, Ohio, USA.
Diana B CherbavazGenomic Health, Inc., Redwood City, California, USA.
Nan ZhangGenomic Health, Inc., Redwood City, California, USA.
Dejan KnezevicGenomic Health, Inc., Redwood City, California, USA.
Phillip G FebboGenomic Health, Inc., Redwood City, California, USA.
Mark LeeGenomic Health, Inc., Redwood City, California, USA.
Hugh Jeffrey LawrenceGenomic Health, Inc., Redwood City, California, USA.
Eric A KleinGlickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, Ohio, USA.
Genomic Health (United States) · USCleveland Clinic · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeWe evaluated gene expression in histologically normal-appearing tissue (NT) adjacent to prostate tumor in radical prostatectomy specimens, assessing for biological significance based on prediction of clinical recurrence (cR - metastatic disease or local recurrence).

resultsA total of 410 evaluable patients had paired tumor and NT. Forty-six genes, representing diverse biological pathways (androgen signaling, stromal response, stress response, cellular organization, proliferation, cell adhesion, and chromatin remodeling) were associated with cR in NT (FDR < 20%), of which 39 concordantly predicted cR in tumor (FDR < 20%). Overall GPS and its stromal response and androgen-signaling gene group components also significantly predicted time to cR in NT (RM-corrected HR/20 units = 1.25; 95% CI: 1.01-1.56; P = 0.024). EXPERIMENTAL

designExpression of 732 genes was measured by quantitative reverse transcriptase polymerase chain reaction (RT-PCR) separately in tumor and adjacent NT specimens from 127 patients with and 374 without cR following radical prostatectomy for T1/T2 prostate cancer. A 17-gene expression signature (Genomic Prostate Score [GPS]), previously validated to predict aggressive prostate cancer when measured in tumor tissue, was also assessed using pre-specified genes and algorithms. Analysis used Cox proportional hazards models, Storey's false discovery rate (FDR) control, and regression to the mean (RM) correction.

conclusionsGene expression profiles, including GPS, from NT adjacent to tumor can predict prostate cancer outcome. These findings suggest that there is a biologically significant field effect in primary prostate cancer that is a marker for aggressive disease.

Indexed as

Gene Expression Regulation, NeoplasticReverse Transcriptase Polymerase Chain ReactionTranscriptomeAdultAgedBiomarkers, TumorDisease ProgressionGene Expression ProfilingHumansMaleMiddle AgedNeoplasm MetastasisNeoplasm Recurrence, LocalPredictive Value of TestsProportional Hazards ModelsProstateBiomarkers, Tumorgene expression profilingmolecular diagnosticsprognosisprostate cancerrisk assessment

Identifiers

PMID27121323
PMCPMC5085124
OpenAlexW2340471075

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.